# Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT Genotype

> **NCT03608878** · PHASE2 · TERMINATED · sponsor: **Chang Gung Memorial Hospital** · enrollment: 5 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** adagloxad simolenin/OBI-821
- **PROCEDURE:** TACE

## Key facts

- **NCT ID:** NCT03608878
- **Lead sponsor:** Chang Gung Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-26
- **Primary completion:** 2019-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** The biopsies in the first 5 screened patients were all negative for Globo-H, of which positive is required to include the patients.
- **Last updated:** 2021-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03608878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03608878, "Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT Genotype". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03608878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*